Pluristem Therapeutics Inc. (PSTI)

0.60
NASDAQ : Health Technology
Prev Close 0.60
Day Low/High 0.58 / 0.63
52 Wk Low/High 0.50 / 1.38
Avg Volume 395.00K
Exchange NASDAQ
Shares Outstanding 149.74M
Market Cap 89.47M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Pluristem Granted Key U.S. Patent For The Treatment Of Peripheral Artery Disease

Exclusive Rights to Treat PAD With Placental Cells in the U.S.

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

Pre-Clinical Studies Conducted at New York's Hospital for Special Surgery

Pluristem Awarded A $3.3 Million Grant By Israeli Government

Pluristem Awarded A $3.3 Million Grant By Israeli Government

Supports Expanding Product Portfolio in Both Clinical Trials and Pre-Clinical R&D

Pluristem Completes Enrollment For Phase I/II Muscle Injury Trial

Pluristem Completes Enrollment For Phase I/II Muscle Injury Trial

Study Conducted in Germany Marks the First Time PLX-PAD Cells are Used for the Treatment of Surgically Induced Muscle Trauma

Pluristem Enters Into Strategic Partnership And Licensing Agreement With Cha Bio&Diostech For The Development And Commercialization Of PLX Cells For The Treatment Of CLI And IC In South Korea

Pluristem Enters Into Strategic Partnership And Licensing Agreement With Cha Bio&Diostech For The Development And Commercialization Of PLX Cells For The Treatment Of CLI And IC In South Korea

Cha Will Conduct and Fund Multiple Peripheral Artery Disease Clinical Trials and Invest $10 Million Valued at $4/Share Into Pluristem Via a Share Exchange Agreement

Pluristem's Preclinical Results For Its PLX-RAD Cells Published In The Journal PLOS ONE

Pluristem's Preclinical Results For Its PLX-RAD Cells Published In The Journal PLOS ONE

Pluristem's Cells Were Reported to Serve as Highly Effective "Off the Shelf" Therapy to Treat Acute Radiation Syndrome and Radiation Induced Bone Marrow Failure in Animals

Pluristem To Present At FDA Symposium

Pluristem To Present At FDA Symposium

Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia

Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia

No Treatment Exists Today for the Most Common Medical Complication of Pregnancy

Pluristem Develops PLX-RAD Cells For Use In Hematology

Pluristem Develops PLX-RAD Cells For Use In Hematology

Enhancing Hematopoietic Stem Cell Engraftment Will be the First Indication

Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine

Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine

Pluristem Plans to Initiate a Phase I Trial in Rotator Cuff Injuries

Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury

Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury

First Time Surgically Induced Muscle Injury Treated With PLX Cells

United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension

United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension

PLX Cells to be Administered Intravenously to Humans for the First Time, Opening Potential New Fields of Applications

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

CORRECTING AND REPLACING -- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

CORRECTING AND REPLACING -- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Industry Executives to Address Whether Stem Cell Therapies Can Turn the Traditional Pharma Model on Its Head

Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Industry Executives to Address Whether Stem Cell Therapies Can Turn the Traditional Pharma Model on Its Head

Pluristem Receives Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Germany

Pluristem Receives Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Germany

International Study Extends FDA Phase II Trial That Began in U.S.

TheStreet Quant Rating: D- (Sell)